A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
NCT07808697
This study is recruiting at 10 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SARS-CoV-2
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 6 months to 11 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- ModernaTX, Inc.
- Last updated on ClinicalTrials.gov
- October 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Orange County Research Center · Ontario, CA
Florida · 4
- Hope Research Network · Miami, FL
- Spotlight Research Center - Internal Medicine · Miami, FL
- Indago Research and Health Cen · Miami Lakes, FL
- MplusM - D&H Tamarac Research Center · Tamarac, FL
Michigan · 1
- Great Lakes Research Institute -Southfield · Southfield, MI
Texas · 2
- REX Clinical Trials · Beaumont, TX
- PanAmerican Clinical Research, LLC. · Brownsville, TX
Utah · 1
- South Ogden Family Medicine · South Ogden, UT
Virginia · 1
- Clinical Research Partners · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.